BioXcel Therapeutics, Inc. (BTAI) News
Filter BTAI News Items
BTAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BTAI News Highlights
- For BTAI, its 30 day story count is now at 3.
- Over the past 6 days, the trend for BTAI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BTAI are CONN, DEC and DRUG.
Latest BTAI News From Around the Web
Below are the latest news stories about BIOXCEL THERAPEUTICS INC that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day TodayCompany to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment for chronic use Dr. Sandra Comer to discuss BXCL501 as a potential treatment for opioid withdrawal NEW HAVEN, Conn., Dec. 12, 2023 (GLOBE NEWSWIRE) -- As previously announced, BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformativ |
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage ProgramsVincent J. O’Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO and Board of Directors NEW HAVEN, Conn., Dec. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced a key executive promotion and a clinical advisor appoin |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment Dr. Sandra Comer to discuss BXCL501 as a potential treatment for opioid withdrawal NEW HAVEN, Conn., Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-on |
7 Penny Stocks With Low Floats and High Short InterestIs the 'smart money' on the money shorting these low-float penny stocks, or is there the opportunity for a short squeeze? |
BTAI: Alignment with FDA on At-Home Study of BXCL501 in Alzheimer’s Agitation…By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Alignment with FDA on Path Forward for TRANQUILITY and SERENITY At-Home Studies BioXcel Therapeutics, Inc. (NASDAQ:BTAI) recently conducted a meeting with the FDA regarding the development pathway for BXCL501 for the treatment of agitation associated with Alzheimer’s disease (AD). Following receipt of the meeting |
BioXcel Therapeutics Third Quarter 2023 Earnings: Misses ExpectationsBioXcel Therapeutics ( NASDAQ:BTAI ) Third Quarter 2023 Results Key Financial Results Net loss: US$50.5m (loss widened... |
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call TranscriptBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations were $-1.29. Operator: Good morning, and welcome to the BioXcel Therapeutics Conference Call, which will cover its alignment with the FDA on its TRANQUILITY program, provide an update on strategic […] |
Q3 2023 BioXcel Therapeutics Inc Earnings CallQ3 2023 BioXcel Therapeutics Inc Earnings Call |
BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic UpdatesAligns with FDA Recommendations and Secures Strategic Financing Terms |